Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy EOLS?
Source: seekingalpha
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.350
Low
18.00
Averages
19.25
High
20.00
Current: 5.350
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolus Sees Growing Demand for Beauty Products
- Profitability Achievement: Evolus achieved profitability in Q4 with an operating profit of $4.2 million, a significant turnaround from a $2.3 million loss in the prior year, indicating effective cost management and market adaptation.
- Revenue Growth: The company reported a 14% year-over-year revenue increase to $90.3 million in Q4, reflecting strong consumer demand for its beauty products, particularly those targeting wrinkles and frown lines.
- Future Outlook: Evolus expects revenue to grow by 10% to 13% in 2026, targeting between $327 million and $337 million, demonstrating confidence in future market potential and a strategic plan for sustainable profitability.
- Customer Satisfaction: With a reorder rate of approximately 71%, Evolus shows high customer satisfaction with its products, which will help solidify its market position in the competitive beauty industry.
See More
Evolus Achieves Profitability, Shares Surge 35%
- Profitability Milestone: Evolus achieved an operating profit of $4.2 million in Q4, a significant turnaround from a $2.3 million loss in the previous year, reflecting effective cost management and market alignment, which boosts investor confidence.
- Significant Revenue Growth: The company reported a 14% year-over-year revenue increase to $90.3 million in Q4, indicating a rising demand for its beauty products and solidifying its position in the aesthetics market.
- High Customer Satisfaction: With a reorder rate of approximately 71%, Evolus demonstrates strong customer satisfaction with its products, which not only enhances brand loyalty but also has the potential to drive future sales growth.
- Optimistic Future Outlook: Evolus anticipates a revenue increase of 10% to 13% by 2026, projecting between $327 million and $337 million, indicating a positive outlook for sustainable profitability and free cash flow, reinforcing its long-term value creation strategy.
See More
Evolus Shares Surge 36% After Exceeding Q4 2025 Earnings Expectations
- Strong Earnings Report: Evolus reported $90.3 million in revenue for Q4 2025, exceeding market expectations by $0.7 million and reflecting approximately 14% year-over-year growth, driven by increased sales of its anti-wrinkle product Jeuveau, indicating a significant improvement in overall performance.
- First Profit in Years: The company achieved a net income of $130,000 for the first time in nearly five years, compared to a net loss of $6.7 million in the same period last year, marking a substantial turnaround in its financial health and boosting investor confidence.
- Slight Margin Decline: Despite achieving profitability, gross margin slipped to 65.7% from 66.7% a year ago, indicating rising cost pressures that could impact future profitability.
- Positive Future Outlook: Evolus projects net revenue between $327 million and $337 million for 2026, suggesting a year-over-year growth rate of 10% to 13%, with total net revenue expected to reach $450 million to $500 million by 2028, reflecting a three-year CAGR of 15% to 19%.
See More
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
Evolus Sees Growing Demand for Beauty Products
- Profitability Achievement: Evolus achieved profitability in Q4 with an operating profit of $4.2 million, a significant turnaround from a $2.3 million loss in the prior year, indicating effective cost management and market adaptation.
- Revenue Growth: The company reported a 14% year-over-year revenue increase to $90.3 million in Q4, reflecting strong consumer demand for its beauty products, particularly those targeting wrinkles and frown lines.
- Future Outlook: Evolus expects revenue to grow by 10% to 13% in 2026, targeting between $327 million and $337 million, demonstrating confidence in future market potential and a strategic plan for sustainable profitability.
- Customer Satisfaction: With a reorder rate of approximately 71%, Evolus shows high customer satisfaction with its products, which will help solidify its market position in the competitive beauty industry.
See More
Evolus Achieves Profitability, Shares Surge 35%
- Profitability Milestone: Evolus achieved an operating profit of $4.2 million in Q4, a significant turnaround from a $2.3 million loss in the previous year, reflecting effective cost management and market alignment, which boosts investor confidence.
- Significant Revenue Growth: The company reported a 14% year-over-year revenue increase to $90.3 million in Q4, indicating a rising demand for its beauty products and solidifying its position in the aesthetics market.
- High Customer Satisfaction: With a reorder rate of approximately 71%, Evolus demonstrates strong customer satisfaction with its products, which not only enhances brand loyalty but also has the potential to drive future sales growth.
- Optimistic Future Outlook: Evolus anticipates a revenue increase of 10% to 13% by 2026, projecting between $327 million and $337 million, indicating a positive outlook for sustainable profitability and free cash flow, reinforcing its long-term value creation strategy.
See More
Evolus Shares Surge 36% After Exceeding Q4 2025 Earnings Expectations
- Strong Earnings Report: Evolus reported $90.3 million in revenue for Q4 2025, exceeding market expectations by $0.7 million and reflecting approximately 14% year-over-year growth, driven by increased sales of its anti-wrinkle product Jeuveau, indicating a significant improvement in overall performance.
- First Profit in Years: The company achieved a net income of $130,000 for the first time in nearly five years, compared to a net loss of $6.7 million in the same period last year, marking a substantial turnaround in its financial health and boosting investor confidence.
- Slight Margin Decline: Despite achieving profitability, gross margin slipped to 65.7% from 66.7% a year ago, indicating rising cost pressures that could impact future profitability.
- Positive Future Outlook: Evolus projects net revenue between $327 million and $337 million for 2026, suggesting a year-over-year growth rate of 10% to 13%, with total net revenue expected to reach $450 million to $500 million by 2028, reflecting a three-year CAGR of 15% to 19%.
See More
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
